Global CRO Discusses
New Approaches to Maximizing Drug Pipelines and Forging Collaborative
Alliances, Highlights Growing Asia/Pacific Region
Raleigh, N.C., June 21, 2012 - INC
Research, LLC, a therapeutically focused clinical research organization
(CRO) with a Trusted ProcessR for delivering reliable results, will
be showcasing the latest innovations in clinical trial development
and partnering strategies at the 2012 DIA Annual
Meeting from June 24 - 28 at the Pennsylvania Convention Center in
Philadelphia.
INC Research executives will be available at booth
#1901 to advance the conversation on maximizing drug pipelines, including
innovative alliance models that drive efficiencies and regional expertise in
underutilized areas to optimize drug development efforts.
"CROs are no longer simply considered simply
clinical trial outsourcing vendors. Rather, sponsors are looking to CROs to
bring new tools and approaches to the table for a competitive edge when
bringing drugs to market," said James Ogle, CEO, INC Research. "On
top of our deep therapeutic expertise, global capabilities and operational
excellence, we are at the forefront of innovation for all stages of the
clinical trial process - from concept through commercialization. We always look
forward to DIA as a forum to share our insights and engage on a deeper level of
discussion to propel the industry forward."
In particular, INC Research representatives will be
available to discuss recent developments in:
- Strategic alliances - Compare and contrast the
current prevailing partnership models and how they apply in different
scenarios: Clinical delivery alliances, asset transfer alliances and Functional
Service Provider (FSP) relationships.
- Conducting trials in Asia/Pacific - Examine risks
and rewards of navigating new global regions, regulatory environments and local
population nuances across Australia, China and India.
- Risk-based monitoring - Deliberate
alternative monitoring approaches based on recent guidance for source
verification, including Targeted Source Document Verification (TSDV) and
"triggered" monitoring.
The Company's thought leaders are also participating
in several educational sessions focusing on a range of topics from innovative
partnering models and advances in adaptive clinical trial design to regulatory
reform for medical devices in Asia.
Speaker Sessions:
Tim Dietlin, Vice President, Alliance Development, INC
Research
- "Risk-sharing Partnerships in Drug Development and
Commercialization," June 27 at 8 a.m.
- "Preferred Provider Relationships: Yesterday's Obstacles, Today's
Successes and Tomorrow's Vision," June 28 at 10:45 p.m.
William K. Sietsema, PhD, Vice President, Regulatory
Strategy, Consulting and Submissions, INC Research
- "Managing Drug Development Portfolios in a Safety-Heightened
Environment," featuring Keith Ruark, VP, AVOS Consulting as a presenter,
June 28 at 9 a.m.
- "Strategically Reduce Cost by Controlling Study Design Cost Drivers
with Attention to Studies with Biomarkers," June 28 at 10:45 p.m.
Alan Touch, OD, Principal Strategist, Medical
Devices and In-Vitro Diagnostics, INC Research
- "Current Advancement of Regulatory Reform for Medical Devices in
Asia and Its Strategic Impact," June 27 at 10 a.m.
John Whitaker, PhD, Vice President, Clinical
Innovation, INC Research
- "Recent Advances in Adaptive Clinical Trial Designs for Medical
Writers," June 27 at 3:30 p.m.
Dawn Pirozzi Maxemow, Senior Medical Writing QR
Specialist, INC Research
- "Medical Writing Competencies and Best Practices in the Global
Environment," June 28 at 10:45 a.m.
For more information or to schedule a meeting at DIA
2012, visit the INC Research site.
About INC Research
INC Research is a therapeutically focused clinical
research organization with a high-performance reputation for conducting global clinical development
programs of the highest integrity. Pharmaceutical and biotechnology
companies look to INC Research for a complete range of customized Phase I through Phase
IV programs in all therapeutic
areas and innovative pediatric and women's health trials. The
Company's Trusted
ProcessR methodology
and therapeutic foresight lead customers to more confident, better-informed
drug and device development decisions. INC Research is headquartered in
Raleigh, NC. For more information, please visit www.incresearch.com or follow us
at @inc_research.
Contact: Lori Dorer,
Media (513) 345-1685
No comments:
Post a Comment